Verteporfin
As of the edition of 20 October 2026, Verteporfin is a small molecule: marketed, first approved in 1999 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2000
- Kind
- Small molecule
- Brand name
- Visudyne
- First approved
- 15 December 1999 (CH)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- Cheplapharm Arzneimittel; 3 holders in all
- Registered trials
- 41, 8 stopped early
- Disease areas
- Eye; Cancer; Skin and connective tissue; Digestive system; Hormones; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 2 | 0 | 2 |
| Phase 1 | 3 | 1 | 0 | 1 |
| Phase 2 | 19 | 10 | 6 | 2 |
| Phase 3 | 5 | 3 | 0 | 1 |
| Phase 4 | 7 | 5 | 0 | 2 |
| All trials | 41 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Qlt | Earlier holder | 2000 to now |
| Cheplapharm Arzneimittel | Applicant | 2000 to now |
| Bausch Health | Acquired holder | 2024 to now |